Citations

Abstract Funding Acknowledgements None. Background Hyperoxemia (a high PaO2, i.e. >200-300 mmHg) has been associated with adverse outcomes in general critical care settings as well as in acute cardiovascular care conditions. The association between hyperoxemia and mortality has not been characterized in the heterogeneous population admitted to the cardiac intensive care unit (CICU). We aimed to examine the association between hyperoxemia on CICU admission with in-hospital mortality. Methods We retrospectively analyzed Mayo Clinic CICU patients from January 2007 to April 2018. PaO2 closest on admission was analyzed as a continuous variable (per 100 mmHg) and categorized as: 60-100 mmHg (51.9%), 101-150 mmHg (28.6%), 151-200 mmHg (10.6%), 201-300 mmHg (6.4%), and >300 mmHg (2.5%). Those without PaO2 on admission and those with hypoxemia were excluded. The primary outcome was all-cause in-hospital mortality evaluated using logistic regression, after adjusting for age, Charlson Comorbidity Index, M-CARS, and use of IMV and NIPPV. Results A total of 3,368 patients were included (median 70.3 years, 39.4% women). Admission diagnoses included ACS (37.0%, with 19.8% STEMI), HF (67.8%), shock (33.0%) and cardiac arrest (25.3%). Median admission PaO2 was 99 (IQR 78, 136) mmHg, with no difference in median PaO2 between hospital survivors and inpatient deaths (99 versus 98, p = 0.38). A J-shaped relationship was observed between admission PaO2 and in-hospital mortality (Figure A), with slightly higher mortality below 100 mmHg and incrementally higher mortality above this threshold (esp. at >200 mmHg). The incremental association between higher PaO2 and mortality (adjusted OR 1.17 per 100 mmHg higher, 95% CI 1.01-1.34, P = 0.03) was focused in the highest PaO2 group (i.e., >300 mmHg; Figure B). Conclusion Hyperoxia (esp. PaO2 >300 mmHg) on CICU admission is associated with increased in-hospital mortality, demonstrating a J-shaped association with an inflection point of lowest mortality around 100 mmHg. Further studies are warranted to assess if specific oxygen targets influence outcomes in critically ill cardiac patients.

Introduction: Studies have demonstrated an association between hyperkalemia and increased mortality in patients with myocardial infarction, but limited data exist regarding hyperkalemia and associated death among unselected cardiac intensive care unit (CICU) patients. Hypothesis: Hyperkalemia is associated with mortality in CICU patients. Methods: Historical cohort of 9,681 CICU patients admitted from January 2007 to December 2015 with serum potassium measured on admission. Hyperkalemia was defined as admission potassium >=5.0 mEq/L, normokalemia as admission potassium 3.5-4.9 mEq/L, and hypokalemia as admission potassium <3.5 mEq/L. Multivariate logistic regression was used to determine predictors of hospital mortality. Post-discharge survival was assessed using Kaplan-Meier analysis and Cox proportional hazards models. Results: Mean age was 67±15 years with 3,629 (36%) females and hospital mortality of 9%. Hyperkalemia occurred in 1,187 (12.3%), and hypokalemia occurred in 719 (7.4%). Compared to normokalemic patients, both hyperkalemic patients (unadjusted OR 2.85, 95% CI 2.40-3.39; P<.001) and hypokalemic patients (unadjusted OR 2.31, 95% CI 1.85-2.88; P<.001) were at increased risk of hospital mortality. After adjustment for illness severity and renal function, only hyperkalemic patients were at increased risk of hospital death (adjusted OR 1.35, 95% CI 1.07-1.69; p = 0.01), while hypokalemic patients were not (P = NS). Among hospital survivors, hyperkalemic patients had lower post-discharge survival by Kaplan-Meier analysis (P <0.001), while hypokalemic patients had similar survival compared to normokalemic patients (p = NS). After adjustment for illness severity and renal function, hospital survivors with hyperkalemia were at increased risk for post-discharge mortality compared with normokalemic patients (adjusted HR 1.16, 95% CI 1.05-1.28; p=.003). Conclusions: Hyperkalemia on CICU admission is associated with higher hospital and post-discharge mortality, independent of renal function and illness severity. This emphasizes the importance of potassium abnormalities as a risk predictor in patients admitted to the CICU.

Background: Troponin-T (TnT) elevation is common in severe sepsis and septic shock, but the impact on mortality and other clinical outcomes remains uncertain. Methods: This was a retrospective review of adult patients with severe sepsis and septic shock admitted to all the intensive care units (ICU) at Mayo Clinic, Rochester from January 2012 to December 2014. Patients with congenital heart disease or pre-existing moderate or greater valvular disease were excluded. TnT elevation was defined as initial TnT ≥0.1 ng/mL or rise in 3- and 6-hour TnT ≥0.03 ng/mL. Primary outcomes included ICU, hospital, 28-day and 1-year mortality and secondary outcomes were need for and duration of non-invasive ventilation or invasive mechanical ventilation, ICU readmission, and ICU and hospital length of stay. Two-tailed p <0.05 was considered statistically significant. Results: During this three-year period, TnT was measured in 372/765 patients (49%) with septic shock with TnT elevation noted in 329/372 (88%) patients. In patients with and without TnT elevation, initial TnT was 0.14±0.26 vs. 0.14±0.02 ng/mL, p =0.57 and peak TnT was 0.20±0.36 vs. 0.08±0.11 ng/mL, p <0.001. Severity of illness scores, laboratory values, vasopressor use, clinical parameters and medications were similar between patients with and without TnT elevation, except that patients with TnT elevation were older and had more frequent history of coronary atherosclerosis, chronic kidney disease, heart failure and atrial fibrillation (all p <0.05). There was no significant difference in ICU mortality [43 (13%) vs. 8 (19%), p =0.34] and hospital mortality [75 (23%) vs. 12 (28%), p =0.45] between patients with and without TnT elevation. Long-term follow-up of 220/329 (67%) patients showed no significant difference in 28-day mortality [97/216 (45%) vs. 1/4 (25%); p =0.63] or 1-year mortality [163/216 (75%) vs. 4/4 (100%); p =0.58]. There was no significant difference in any of the secondary outcomes between patients with and without elevated TnT (all p >0.05). There was no difference in mortality with increasing quartiles of peak TnT. Conclusions: Troponin elevation is associated with older age and higher comorbidity burden, but does not predict mortality in patients with severe sepsis and septic shock.

ABSTRACT Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.

*Nature Reviews Nephrology* welcomes you to this webinar, in which our two speakers — Leo Celi and Kianoush Kashani — will present on the theme of Digital Determinants of Health, with a focus on artificial intelligence (AI) and the need for equity-focused innovation. The webinar will be held on 14th of March 2024 — World Kidney Day — which this year focuses on “Advancing equitable access to care and optimal medication practice”. In their [Comment](https://www.nature.com/articles/s41581-023-00763-4.epdf?sharing_token=ihZn7Tzp1ixBfK7a3X_6x9RgN0jAjWel9jnR3ZoTv0NaWQBzIFRPdPKT7AS3IVVHez49nwrLVjZJyLsCUt5034qu70IjW6yS7U3gUuTEQjm0O_u1j1PiMZLzRs7qKAyY_28RvtE3kXcXmwKeyufyUyKP715Wx73c6p6Bfp6w6Sg%3D) “Digital determinants of health: opportunities and risks amidst health inequities”, Leo Celi and colleagues argue that given the current digital revolution, digital tools and AI applications in health care must be developed with equity at the forefront to avoid perpetuating historical biases and inequities. With their [Consensus Statement](https://www.nature.com/articles/s41581-023-00744-7) on “Digital health and acute kidney injury”, Kianoush Kashani and colleagues highlight some of the potential applications of digital health tools in nephrology, as well as the need for equitable digitization. Artificial Intelligence: The digital determinant of health to rule them all Artificial intelligence (AI) is poised to be the biggest digital determinant of health. From healthcare, to education, to law enforcement, AI can theoretically augment every human task that involves thinking. We will see every decision-making infiltrated by AI. This is why AI is different. Most technologies are much narrower in scope, and therefore, easier to regulate. In addition, the data that we use to build AI reflects everything about the systems we would like to disrupt, both good and bad. Behind the façade of AI lies our legacy systems with all their flaws. The biggest threat to AI delivering its promise stems from the risk of cementing the structural inequities that permeate every aspect of society. AI provides an opportunity to inch us closer to a better care delivery system, but it will require us to design an equity-focused sociotechnical ecosystem. Engineering AI in a vacuum that does not build capacity nor include cultural transformation of how we learn and how we work together will be a waste of time and money, and a huge opportunity cost. To avert the disaster from AI, we need to diversify those sitting at the table. We need to diversify those who are developing and deploying AI. Digital health in acute kidney injury management Acute kidney injury (AKI) is a highly prevalent clinical syndrome that substantially impacts patient outcomes. It is accepted by the clinical communities that the management of AKI is time sensitive. Unfortunately, despite growing proof of its preventability, AKI management remains suboptimal in community, acute care, and post-acute care settings. Digital health solutions comprise various tools and models to improve care processes and patient outcomes in multiple medical fields. AKI development, progression, recovery, or lack thereof, offers tremendous opportunities for developing, validating, and implementing digital health solutions in multiple settings.

The accurate interpretation of CRRT machine alarms is crucial in the intensive care setting. ChatGPT, with its advanced natural language processing capabilities, has emerged as a tool that is evolving and advancing in its ability to assist with healthcare information. This study is designed to evaluate the accuracy of the ChatGPT-3.5 and ChatGPT-4 models in addressing queries related to CRRT alarm troubleshooting. This study consisted of two rounds of ChatGPT-3.5 and ChatGPT-4 responses to address 50 CRRT machine alarm questions that were carefully selected by two nephrologists in intensive care. Accuracy was determined by comparing the model responses to predetermined answer keys provided by critical care nephrologists, and consistency was determined by comparing outcomes across the two rounds. The accuracy rate of ChatGPT-3.5 was 86% and 84%, while the accuracy rate of ChatGPT-4 was 90% and 94% in the first and second rounds, respectively. The agreement between the first and second rounds of ChatGPT-3.5 was 84% with a Kappa statistic of 0.78, while the agreement of ChatGPT-4 was 92% with a Kappa statistic of 0.88. Although ChatGPT-4 tended to provide more accurate and consistent responses than ChatGPT-3.5, there was no statistically significant difference between the accuracy and agreement rate between ChatGPT-3.5 and -4. ChatGPT-4 had higher accuracy and consistency but did not achieve statistical significance. While these findings are encouraging, there is still potential for further development to achieve even greater reliability. This advancement is essential for ensuring the highest-quality patient care and safety standards in managing CRRT machine-related issues.

OBJECTIVES: Among patients with severe acute kidney injury (AKI) admitted to the ICU in high-income countries, regional practice variations for fluid balance (FB) management, timing, and choice of renal replacement therapy (RRT) modality may be significant. DESIGN: Secondary post hoc analysis of the STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial (ClinicalTrials.gov number NCT02568722). SETTING: One hundred-fifty-three ICUs in 13 countries. PATIENTS: Altogether 2693 critically ill patients with AKI, of whom 994 were North American, 1143 European, and 556 from Australia and New Zealand (ANZ). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Total mean FB to a maximum of 14 days was +7199 mL in North America, +5641 mL in Europe, and +2211 mL in ANZ (p < 0.001). The median time to RRT initiation among patients allocated to the standard strategy was longest in Europe compared with North America and ANZ (p < 0.001; p < 0.001). Continuous RRT was the initial RRT modality in 60.8% of patients in North America and 56.8% of patients in Europe, compared with 96.4% of patients in ANZ (p < 0.001). After adjustment for predefined baseline characteristics, compared with North American and European patients, those in ANZ were more likely to survive to ICU (p < 0.001) and hospital discharge (p < 0.001) and to 90 days (for ANZ vs. Europe: risk difference [RD], –11.3%; 95% CI, –17.7% to –4.8%; p < 0.001 and for ANZ vs. North America: RD, –10.3%; 95% CI, –17.5% to –3.1%; p = 0.007). CONCLUSIONS: Among STARRT-AKI trial centers, significant regional practice variation exists regarding FB, timing of initiation of RRT, and initial use of continuous RRT. After adjustment, such practice variation was associated with lower ICU and hospital stay and 90-day mortality among ANZ patients compared with other regions.